Sotac Pharmaceuticals
- Market cap
- ₹ 40 Cr.
- P/E
- 17.2x
- P/B
- 1.06x
- ROE
- 10%
- ROCE
- 13%
- Dividend yield
- 0%
- Debt / equity
- 0.27
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
About
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sotac Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.2 against a typical 34.6: cheaper than most peers (1st = cheapest).45th of 220
- Sales growth+15.4% against a typical +15.6% from a year earlier.100th of 197
- Profit growth0% against a typical +18.9% from a year earlier.102nd of 160
- Size₹ 40.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).167th of 199
Research by Minerva Capital Research Solutions
Our research team's work on Sotac PharmaceuticalsAlso covered in
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 26 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the half year and year ended on March 31, 2026, dividend and other business matters |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters. |
| 28 May 2025 | Financial Results/Dividend/Other business matters | Intimation of Board meeting for consideration of Audited Standalone & Consolidated Financial Results for half year and year ended on March 31, 2025 and Audited Financial Statement of the Company for year ended on March 31, 2025, Dividend and Other Business Matter. |
| 29 Oct 2024 | Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| 13 Aug 2024 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2024 and other business matters |
| 17 May 2024 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2024 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 38 | 52 | 52 | 53 | 47 | 37 | 60 |
| Expenses | 36 | 34 | 47 | 48 | 48 | 35 | 33 | 50 |
| Operating Profit | 3 | 4 | 4 | 4 | 4 | 12 | 4 | 10 |
| OPM % | 9% | 10% | 9% | 8% | 8% | 26% | 10% | 17% |
| Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 |
| Profit before tax | 2 | 2 | 2 | 2 | 3 | 9 | 3 | 5 |
| Tax % | 49% | 34% | 45% | −34% | 30% | 13% | 23% | 31% |
| Net Profit | 2 | 1 | 2 | 3 | 2 | 6 | 2 | 3 |
| EPS in Rs | 6.78 | 1.64 | 1.57 | 2.31 | 1.73 | 5.53 | 2.22 | 3 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 16%
- 3 Years
- 10%
- TTM
- 4%
- 10 Years
- —
- 5 Years
- 35%
- 3 Years
- 31%
- TTM
- −25%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −9%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sotac Pharmaceuticals | — | ₹ 40 Cr. | 17.2x | 1.1x | 10% | — |
| Sun Pharmaceutical Industries | ₹ 1,898.00 | ₹ 4,55,383 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,525.00 | ₹ 2,26,312 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 5,013.00 | ₹ 1,90,672 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,416.00 | ₹ 1,14,392 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,105.00 | ₹ 1,10,224 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Dhananjaya Alli
- Executive Chairman of the Board, Whole-Time Director
- Suneel Pachipala
- Chief Financial Officer
- Barkha Jain
- Compliance Officer, Company Secretary
- Murali Meraga
- Managing Director
- Pavan Sathvik Gilaka
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.